Investigating how glutamine metabolism affects immune cell development in soft-tissue sarcomas
Official title: The Role of Glutamine Metabolism in Monocyte-Derived Dendritic Cell Differentiation in the Soft-Tissue Sarcoma Microenvironment
Funded at University of Pennsylvania · NIH-10888984 · Data updated 2026-11-12
This study is looking at how a nutrient called glutamine affects certain immune cells in soft-tissue sarcoma, with the goal of finding new ways to boost the immune response and improve treatment options for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 8, 2021 |
| Project end | July 7, 2026 |
| Funding year | 2024 |
| Award (this year) | $36,413 |
| NIH project number | 5F30CA265069-04 |
| Project ID | NIH-10888984 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with soft-tissue sarcomas who may be eligible for immunotherapy.
✕Less likely to help
Patients with non-cancerous conditions or those not diagnosed with soft-tissue sarcomas may not receive any benefit from this research.
What this research studies
This research focuses on understanding the role of glutamine metabolism in the differentiation of immune cells called monocyte-derived dendritic cells (Mo-DCs) within the soft-tissue sarcoma (STS) microenvironment. The study aims to uncover the mechanisms that inhibit Mo-DC differentiation, which is crucial for enhancing the effectiveness of immunotherapy in treating STS. By exploring how glutamine is utilized by these immune cells, the research seeks to identify potential therapeutic strategies that could improve patient outcomes. Patients may benefit from insights that could lead to novel treatments targeting the immune response in STS.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for patients with soft-tissue sarcomas.
How similar studies have gone: Previous research has shown promise in enhancing immune responses through metabolic interventions, suggesting potential success for this approach.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Lobel, Graham — University of Pennsylvania
- Study coordinator: Lobel, Graham
Related research
Other NIH-funded projects on the same topics.
-
SPORE in Soft Tissue Sarcoma: targeted therapies and biomarkers to help patients
A big research effort at a major cancer center aims to develop targeted treatments and biomarkers to improve outcomes for people with soft tissue sarcoma.
-
Ultra-steerable ultrasound therapy for soft tissue sarcoma
A new ultrasound device is being developed to non-invasively shrink or remove soft tissue sarcomas while protecting nearby nerves, blood vessels, and bones.
-
Robotic ultrasound system to non-invasively remove soft tissue sarcoma
A robotic ultrasound approach aims to precisely destroy soft tissue sarcoma tumors without open surgery for people with large or hard-to-reach tumors.
-
Boosting NK-cell therapy for soft tissue sarcoma using a dog model
This project combines an antibody that soaks up a tumor-made immune blocker with natural killer (NK) cell therapy to help dogs and, eventually, people with soft tissue sarcoma fight their tumors.
-
Targeted treatments for soft tissue sarcoma
This project is testing targeted drugs and immunotherapies for people with soft tissue sarcoma, including adults and children.
-
Enhancing cancer treatment using natural killer cells in dogs with soft tissue sarcoma
This study is looking at a new way to help treat soft tissue sarcoma in dogs by using special immune cells called natural killer cells, along with a targeted antibody, to make the treatment more effective and hopefully improve outcomes for our furry friends.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.